Publications 2023

Chan GKL, Maisel S, Hwang YC, Pascual BC, Wolber RRB, Vu P, Patra KC, Bouhaddou M, Kenerson HL, Lim HC, Long D, Yeung RS, Sethupathy P, Swaney DL, Krogan NJ, Turnham RE, Riehle KJ, Scott JD, Bardeesy N, Gordan JD (2023)
Oncogenic PKA signaling increases c-MYC protein expression through multiple targetable mechanisms
Elife, 12 (in press)
DOI 10.7554/eLife.69521, PubMed 36692000

Publications 2022

German K, Juul S, Vu P (2022)
Reply
J Pediatr, 243, 238-239
DOI 10.1016/j.jpeds.2022.01.011, PubMed 35041810

Wu Q, Zhen Y, Shi L, Vu P, Greninger P, Adil R, Merritt J, Egan R, Wu MJ, Yin X, Ferrone CR, Deshpande V, Baiev I, Pinto CJ, McLoughlin DE, Walmsley CS, Stone JR, Gordan JD, Zhu AX, Juric D, Goyal L, Benes CH, Bardeesy N (2022)
EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma
Cancer Discov, 12 (5), 1378-1395
DOI 10.1158/2159-8290.CD-21-1168, PubMed 35420673

Publications 2019

Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE et al. (2019)
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma
Cancer Discov, 9 (8), 1064-1079
DOI 10.1158/2159-8290.CD-19-0182, PubMed 31109923

Pham T, Bui L, Nguyen A, Nguyen B, Tran P, Vu P, Dang L (2019)
The prevalence of depression and associated risk factors among medical students: An untold story in Vietnam
PLoS One, 14 (8), e0221432
DOI 10.1371/journal.pone.0221432, PubMed 31430339

Reoma LB, Trindade CJ, Monaco MC, Solis J, Montojo MG, Vu P, Johnson K, Beck E, Nair G, Khan OI, Quezado M, Hewitt SM, Reich DS, Childs R, Nath A (2019)
Fatal encephalopathy with wild-type JC virus and ruxolitinib therapy
Ann Neurol, 86 (6), 878-884
DOI 10.1002/ana.25608, PubMed 31600832

Publications 2017

Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL et al. (2017)
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
Clin Cancer Res, 23 (16), 4662-4670
DOI 10.1158/1078-0432.CCR-17-0160, PubMed 28487444

Publications 2016

Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, Mussolin B, Reyes S, Henderson L, Sun JE, Van Seventer EE, Gurski JM, Baltschukat S, Schacher-Engstler B, Barys L, Stamm C, Furet P, Ryan DP, Stone JR, Iafrate AJ, Getz G et al. (2016)
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
Cancer Discov, 7 (3), 252-263
DOI 10.1158/2159-8290.CD-16-1000, PubMed 28034880

Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å (2016)
TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
Front Genet, 7, 85
DOI 10.3389/fgene.2016.00085, PubMed 27242894

Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo JC, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, Jenkins RL, Rieger-Christ KM, Sullivan TB, Hezel AF, Liss AS, Mizukami Y, Goyal L, Ferrone CR, Zhu AX, Joung JK et al. (2016)
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
Cancer Discov, 6 (7), 727-39
DOI 10.1158/2159-8290.CD-15-1442, PubMed 27231123

Publications 2014

Sørlie T, Johnsen H, Vu P, Lind GE, Lothe R, Børresen-Dale AL (2014)
Mutation screening of the TP53 gene by temporal temperature gel electrophoresis (TTGE)
Methods Mol Biol, 1105, 315-24
DOI 10.1007/978-1-62703-739-6_25, PubMed 24623239

Publications 2009

Zhou W, Muggerud AA, Vu P, Due EU, Sørlie T, Børresen-Dale AL, Wärnberg F, Langerød A (2009)
Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution
Mol Oncol, 3 (3), 214-9
DOI 10.1016/j.molonc.2009.03.001, PubMed 19403344

Publications 2008

Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Børresen-Dale AL, Overgaard J (2008)
A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients
Acta Oncol, 47 (4), 600-7
DOI 10.1080/02841860802047411, PubMed 18465328

Suspitsin EN, Due EU, Vu P, Hirvonen A, Børresen-Dale AL, Imyanitov EN (2008)
TP53 mutations in synchronous and metachronous bilateral breast carcinomas
Cancer Genet Cytogenet, 184 (2), 119-21
DOI 10.1016/j.cancergencyto.2008.03.005, PubMed 18617062

Publications 2007

Edvardsen H, Tefre T, Jansen L, Vu P, Haffty BG, Fosså SD, Kristensen VN, Børresen-Dale AL (2007)
Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence
Radiat Oncol, 2, 25
DOI 10.1186/1748-717X-2-25, PubMed 17623063

Publications 2005

Sørlie T, Johnsen H, Vu P, Lind GE, Lothe R, Børresen-Dale AL (2005)
Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis
Methods Mol Biol, 291, 207-16
DOI 10.1385/1-59259-840-4:207, PubMed 15502225